Abgrall S, Del Giudice P, Melica G, Costagliola D, FHDH-ANRS CO4. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. AIDS. 13 mars 2010;24(5):763‑71. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20087155
Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 15 mai 2010;50(10):1387‑96. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20380565
Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán MA. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6(2):Article 18. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21972433
Colin X, Lafuma A, Costagliola D, Lang J-M, Guillon P. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France. Pharmacoeconomics. 2010;28 Suppl 1(SUPPL. 1):59‑68. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21182344
Colin X, Lafuma A, Costagliola D, Smets E, Mauskopf J, Guillon P. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France. Pharmacoeconomics. 2010;28 Suppl 1(SUPPL. 1):183‑97. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21182351
Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, et al. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy–results from the ANRS CO4 cohort. J Antimicrob Chemother. 11 oct 2010;65(10):2215‑23. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20702463
HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2 janv 2010;24(1):123‑37. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19770621
Kousignian I, Launay O, Mayaud C, Rabaud C, Costagliola D, Abgrall S, et al. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? J Antimicrob Chemother. 10 janv 2010;65(1):138‑44. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/19903719
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 15 mai 2010;24(8):1228‑30. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20400883
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 26 juill 2010;170(14):1228‑38. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20660842
Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2 juin 2010;102(11):784‑92. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20442214
Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, et al. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS. 13 nov 2010;24(17):2697‑704. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20885283
Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, et al. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med. 8 mars 2010;170(5):410‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20212176
Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy–the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med. 23 févr 2010;7(2):e1000239. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20186270
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, et al. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One. 1 oct 2010;5(10):e13132. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/20976112
